Last edition
News about "chronic inflammatory demyelinating polyneuropathy "
argenx Secures FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE
Halozyme Therapeutics has announced that argenx has received US Food and Drug Administration (FDA) approval for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy.
Chronic Inflammatory Demyelinating Polyneuropathy | 24/06/2024 | By Aishwarya | 215
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy